Published in Clin Cancer Res on May 01, 1999
Biofunctionalized magnetic-vortex microdiscs for targeted cancer-cell destruction. Nat Mater (2009) 2.02
Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol (2010) 1.78
Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells. Clin Cancer Res (2012) 1.67
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. N Engl J Med (2016) 1.56
Immunotherapeutic approaches for glioma. Crit Rev Immunol (2009) 1.55
IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13. Neoplasia (2002) 1.42
Engineered herpes simplex virus 1 is dependent on IL13Ralpha 2 receptor for cell entry and independent of glycoprotein D receptor interaction. Proc Natl Acad Sci U S A (2002) 1.39
Detection of cancer cells in the cerebrospinal fluid: current methods and future directions. Fluids Barriers CNS (2011) 1.32
Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells. Clin Cancer Res (2012) 1.29
Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity. Mol Ther (2008) 1.24
Construction and properties of a herpes simplex virus 1 designed to enter cells solely via the IL-13alpha2 receptor. Proc Natl Acad Sci U S A (2006) 1.22
Immunotherapy of malignant brain tumors. Immunol Rev (2008) 1.20
A high-performance nanobio photocatalyst for targeted brain cancer therapy. Nano Lett (2009) 1.19
Combining cytotoxic and immune-mediated gene therapy to treat brain tumors. Curr Top Med Chem (2005) 1.09
Driving CAR T-cells forward. Nat Rev Clin Oncol (2016) 1.09
Interleukin 13 mutants of enhanced avidity toward the glioma-associated receptor, IL13Ralpha2. Neoplasia (2004) 1.07
Multifunctional nanoparticles for brain tumor imaging and therapy. Adv Drug Deliv Rev (2013) 1.07
Gene therapy and targeted toxins for glioma. Curr Gene Ther (2005) 1.02
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma. Clin Cancer Res (2015) 1.00
Characterization of a recombinant herpes simplex virus 1 designed to enter cells via the IL13Ralpha2 receptor of malignant glioma cells. J Virol (2005) 1.00
Gene therapy and targeted toxins for glioma. Curr Gene Ther (2011) 0.97
Encapsulation of a radiolabeled cluster inside a fullerene cage, (177)Lu(x)Lu((3-x))N@C(80): an interleukin-13-conjugated radiolabeled metallofullerene platform. J Am Chem Soc (2010) 0.96
IL-13Rα2-Targeted Therapy Escapees: Biologic and Therapeutic Implications. Transl Oncol (2011) 0.93
An interleukin 13 receptor α 2-specific peptide homes to human Glioblastoma multiforme xenografts. Neuro Oncol (2011) 0.91
The future of glioblastoma therapy: synergism of standard of care and immunotherapy. Cancers (Basel) (2014) 0.91
Toxin-based targeted therapy for malignant brain tumors. Clin Dev Immunol (2012) 0.91
Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC. Clin Cancer Res (2014) 0.91
Protein- and DNA-based active immunotherapy targeting interleukin-13 receptor alpha2. Cancer Biother Radiopharm (2008) 0.87
New agents for targeting of IL-13RA2 expressed in primary human and canine brain tumors. PLoS One (2013) 0.86
Interleukin-13 receptor alpha 2-targeted glioblastoma immunotherapy. Biomed Res Int (2014) 0.86
Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy. Neuro Oncol (2014) 0.84
Herpesvirus vectors for therapy of brain tumors. Open Virol J (2010) 0.84
Molecular targeting of intracellular compartments specifically in cancer cells. Genes Cancer (2010) 0.83
Glioma IL13Rα2 is associated with mesenchymal signature gene expression and poor patient prognosis. PLoS One (2013) 0.83
Integration of epidemiology, immunobiology, and translational research for brain tumors. Ann N Y Acad Sci (2013) 0.82
Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma. Sci Transl Med (2017) 0.78
A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker. Neuro Oncol (2012) 0.78
Neuroimmunology of the Interleukins 13 and 4. Brain Sci (2016) 0.77
Cellular immunotherapy for pediatric solid tumors. Cytotherapy (2014) 0.77
Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation. Anticancer Agents Med Chem (2011) 0.77
Convection-Enhanced Delivery for Diffuse Intrinsic Pontine Glioma Treatment. Curr Neuropharmacol (2017) 0.76
Prioritization schema for immunotherapy clinical trials in glioblastoma. Oncoimmunology (2016) 0.76
Profound tumor-specific Th2 bias in patients with malignant glioma. BMC Cancer (2012) 0.76
Ephs and Ephrins in malignant gliomas. Growth Factors (2014) 0.76
Simultaneous targeting of Eph receptors in glioblastoma. Oncotarget (2016) 0.75
Toward intracellular targeted delivery of cancer therapeutics: progress and clinical outlook for brain tumor therapy. BioDrugs (2012) 0.75
IL13Rα2 signaling in colorectal cancer. Oncoscience (2015) 0.75
Tumor-targeted nanotherapeutics: overcoming treatment barriers for glioblastoma. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2016) 0.75
MRI contrast agent for targeting glioma: interleukin-13 labeled liposome encapsulating gadolinium-DTPA. Neuro Oncol (2015) 0.75
Peptide-based PET imaging of the tumor restricted IL13RA2 biomarker. Oncotarget (2017) 0.75
Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther (2000) 4.33
Bradykinin as a pain mediator: receptors are localized to sensory neurons, and antagonists have analgesic actions. Proc Natl Acad Sci U S A (1988) 2.57
Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J Biol Chem (1996) 2.33
HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3' untranslated regions of cytokine and angiogenic factor mRNAs. Cancer Res (2001) 2.29
A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis. Neurology (2008) 2.21
Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci U S A (1998) 2.11
Human osteoclasts, not osteoblasts, deposit osteopontin onto resorption surfaces: an in vitro and ex vivo study of remodeling bone. J Bone Miner Res (1995) 2.01
Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci U S A (2000) 1.99
Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell (1993) 1.97
Differential gene expression profiling in human brain tumors. Physiol Genomics (2001) 1.88
Rat model of perinatal hypoxic-ischemic brain damage. J Neurosci Res (1999) 1.86
Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology (2000) 1.75
Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions. J Neurochem (1995) 1.65
Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo. J Bone Miner Res (1997) 1.63
Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res (1998) 1.59
Iron in the brain. Nutr Rev (1993) 1.58
Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther (1998) 1.57
Effect of manipulation of iron storage, transport, or availability on myelin composition and brain iron content in three different animal models. J Neurosci Res (2004) 1.57
Receptor-mediated transcytosis of transferrin across the blood-brain barrier. J Neurosci Res (1987) 1.51
Characterization of a novel brain-derived microglial cell line isolated from neonatal rat brain. Glia (2001) 1.51
Human astrocytoma cells express a unique chloride current. Neuroreport (1996) 1.50
Regional brain iron, ferritin and transferrin concentrations during iron deficiency and iron repletion in developing rats. J Nutr (1997) 1.45
Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res (1997) 1.45
Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase. Arthritis Rheum (1998) 1.44
Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/testis antigen. Mol Med (2000) 1.41
Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc Natl Acad Sci U S A (1995) 1.41
The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc Natl Acad Sci U S A (1996) 1.41
Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor. Oncogene (2008) 1.41
A controlled study of efficacy of interstitial or external irradiation in a virus-induced brain-tumor model in rats. J Neurosurg (1989) 1.39
Distribution of divalent metal transporter 1 and metal transport protein 1 in the normal and Belgrade rat. J Neurosci Res (2001) 1.38
Membranes from T and B lymphocytes have different patterns of tyrosine phosphorylation. Proc Natl Acad Sci U S A (1984) 1.38
Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. J Neurosurg (1995) 1.33
Cerebral microenvironment influences expression of the vitronectin gene in astrocytic tumors. J Cell Sci (1995) 1.29
Human malignant glioma therapy using anti-alpha(v)beta3 integrin agents. J Neurooncol (2000) 1.29
Interleukin 1 amplifies receptor-mediated activation of phospholipase A2 in 3T3 fibroblasts. Proc Natl Acad Sci U S A (1988) 1.29
Ferritin: a novel mechanism for delivery of iron to the brain and other organs. Am J Physiol Cell Physiol (2007) 1.29
Novel anti-brain tumor cytotoxins specific for cancer cells. Nat Biotechnol (1998) 1.28
Insight into the pathophysiology of restless legs syndrome. J Neurosci Res (2000) 1.26
Surgically induced osteoarthritis in the rat results in the development of both osteoarthritis-like joint pain and secondary hyperalgesia. Osteoarthritis Cartilage (2006) 1.26
Genetically engineered HSV in the treatment of glioma: a review. Rev Med Virol (2000) 1.24
Antisense wnt-5a mimics wnt-1-mediated C57MG mammary epithelial cell transformation. Exp Cell Res (1998) 1.24
Induction and expression of human cartilage glycoprotein 39 in rheumatoid inflammatory and peripheral blood monocyte-derived macrophages. Exp Cell Res (1997) 1.22
Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells. Biochem Pharmacol (1998) 1.20
Inflammatory cells in solid murine neoplasms. II. Cell types found throughout the course of Moloney sarcoma regression or progression. Int J Cancer (1976) 1.20
High-resolution longitudinal assessment of flow and permeability in mouse glioma vasculature: Sequential small molecule and SPIO dynamic contrast agent MRI. Magn Reson Med (2009) 1.19
Selective inhibition of inducible nitric oxide synthase reduces progression of experimental osteoarthritis in vivo: possible link with the reduction in chondrocyte apoptosis and caspase 3 level. Arthritis Rheum (2000) 1.19
Selective inhibition of inducible nitric oxide synthase in experimental osteoarthritis is associated with reduction in tissue levels of catabolic factors. J Rheumatol (1999) 1.18
Studies on the role of macrophages in regulation of growth and metastasis of murine chemically induced fibrosarcomas. Int J Cancer (1975) 1.16
Mitogenic activity elaborated by macrophage-like cell lines acts as competence factor(s) for BALB/c 3T3 cells. J Cell Physiol (1982) 1.15
Viruses and the versatile macrophage. Br Med Bull (1985) 1.15
Inflammatory cells in solid murine neoplasms. IV. Cytolytic T lymphocytes isolated from regressing or progressing Moloney sarcomas. J Immunol (1977) 1.14
Identification and cloning of a connective tissue growth factor-like cDNA from human osteoblasts encoding a novel regulator of osteoblast functions. J Biol Chem (1999) 1.14
Mechanisms and regulation of transferrin and iron transport in a model blood-brain barrier system. Neuroscience (2003) 1.14
NPC 15669 inhibits the reversed passive Arthus reaction in rats by blocking neutrophil recruitment. J Pharmacol Exp Ther (1992) 1.12
Acute and chronic effects of developmental iron deficiency on mRNA expression patterns in the brain. J Neural Transm Suppl (2006) 1.12
Cellular distribution of ferritin subunits in postnatal rat brain. J Comp Neurol (1998) 1.11
Variations in dietary iron alter brain iron metabolism in developing rats. J Nutr (2000) 1.11
Do oligodendrocytes mediate iron regulation in the human brain? Ann Neurol (1989) 1.10
Inflammatory cells in solid murine neoplasms. III. Cytotoxicity mediated in vitro by macrophages recovered from disaggregated regressing Moloney sarcomas. J Immunol (1977) 1.09
Cellular iron status influences the functional relationship between microglia and oligodendrocytes. Glia (2006) 1.09
Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors. Cancer Res (1999) 1.09
N-(fluorenyl-9-methoxycarbonyl) amino acids, a class of antiinflammatory agents with a different mechanism of action. Proc Natl Acad Sci U S A (1991) 1.08
Existing and emerging mechanisms for transport of iron and manganese to the brain. J Neurosci Res (1999) 1.08
Expression of a restrictive receptor for interleukin 13 is associated with glial transformation. J Neurooncol (2000) 1.08
Expression of voltage-activated chloride currents in acute slices of human gliomas. Neuroscience (1998) 1.08
Iron and neurodegenerative disorders. Brain Res Bull (2001) 1.08
Abnormal localization of iron regulatory protein in Alzheimer's disease. Brain Res (1998) 1.08
Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virus. Clin Cancer Res (1999) 1.07
Iron, transferrin, and ferritin in the rat brain during development and aging. J Neurochem (1994) 1.06
Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors. Cancer Gene Ther (2006) 1.05
Evidence for mononuclear phagocytes in solid neoplasms and appraisal of their nonspecific cytotoxic capabilities. Contemp Top Immunobiol (1980) 1.04
In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase. Hum Gene Ther (1997) 1.03
Up-regulation of urokinase and urokinase receptor genes in malignant astrocytoma. Am J Pathol (1995) 1.03
Cellular distribution of iron in the brain of the Belgrade rat. Neuroscience (1999) 1.03
Identification and initial characterization of 5000 expressed sequenced tags (ESTs) each from adult human normal and osteoarthritic cartilage cDNA libraries. Osteoarthritis Cartilage (2001) 1.02
Macrophage-derived growth factor for fibroblasts and Interleukin-1 are distinct entities. J Leukoc Biol (1984) 1.02
Identification and localization of divalent metal transporter-1 (DMT-1) in term human placenta. Placenta (2000) 1.01
Malignant human gliomas express an amiloride-sensitive Na+ conductance. Am J Physiol (1999) 1.00
Fas-induced expression of chemokines in human glioma cells: involvement of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase. Cancer Res (2001) 0.99
Receptor for interleukin 13 is abundantly and specifically over-expressed in patients with glioblastoma multiforme. Int J Oncol (1999) 0.99
Brain edema in meningiomas is associated with increased vascular endothelial growth factor expression. Neurosurgery (1997) 0.99
Ferritin, transferrin, and iron in selected regions of the adult and aged rat brain. J Comp Neurol (1993) 0.99
The distribution of transferrin immunoreactivity in the rat central nervous system. Brain Res (1986) 0.98
Distribution of divalent metal transporter-1 in the monkey basal ganglia. Neuroscience (2004) 0.97
Changes in iron histochemistry after hypoxic-ischemic brain injury in the neonatal rat. J Neurosci Res (1999) 0.97
CKbeta-8 [CCL23], a novel CC chemokine, is chemotactic for human osteoclast precursors and is expressed in bone tissues. J Cell Physiol (2000) 0.95
VEGF-D is an X-linked/AP-1 regulated putative onco-angiogen in human glioblastoma multiforme. Mol Med (2001) 0.95
Oligodendrocyte progenitor cells internalize ferritin via clathrin-dependent receptor mediated endocytosis. J Neurosci Res (2000) 0.95
Human osteoclast cathepsin K is processed intracellularly prior to attachment and bone resorption. J Bone Miner Res (2001) 0.94
Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses. Gene Ther (2007) 0.94
Aluminum access to the brain: a role for transferrin and its receptor. Proc Natl Acad Sci U S A (1990) 0.94
2,6-Diamino-N-([1-(1-oxotridecyl)-2-piperidinyl] methyl)hexanamide (NPC 15437): a novel inhibitor of protein kinase C interacting at the regulatory domain. Mol Pharmacol (1992) 0.94
In vitro and in vivo gene delivery mediated by a synthetic polycationic amino polymer. Nat Biotechnol (1997) 0.93
Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1. Gene Ther (2011) 0.93
pH alterations "reset" Ca2+ sensitivity of brain Na+ channel 2, a degenerin/epithelial Na+ ion channel, in planar lipid bilayers. J Biol Chem (2001) 0.93